Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy–a literature review
IEC Verhaart, A Robertson, IJ Wilson… - Orphanet journal of rare …, 2017 - Springer
Spinal muscular atrophy linked to chromosome 5q (SMA) is a recessive, progressive,
neuromuscular disorder caused by bi-allelic mutations in the SMN1 gene, resulting in motor …
neuromuscular disorder caused by bi-allelic mutations in the SMN1 gene, resulting in motor …
Drug repurposing for rare diseases
HI Roessler, NVAM Knoers, MM van Haelst… - Trends in …, 2021 - cell.com
Currently, there are about 7000 identified rare diseases, together affecting 10% of the
population. However, fewer than 6% of all rare diseases have an approved treatment option …
population. However, fewer than 6% of all rare diseases have an approved treatment option …
Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy
JR Mendell, SA Al-Zaidy, KJ Lehman, M McColly… - JAMA …, 2021 - jamanetwork.com
Importance This ongoing study assesses long-term safety and durability of response in
infants with spinal muscular atrophy (SMA) type 1 after dosing with onasemnogene …
infants with spinal muscular atrophy (SMA) type 1 after dosing with onasemnogene …
Spinal muscular atrophy—insights and challenges in the treatment era
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by
deletion or mutation of SMN1. Four subtypes exist, characterized by different clinical …
deletion or mutation of SMN1. Four subtypes exist, characterized by different clinical …
Advances in treatment of spinal muscular atrophy–new phenotypes, new challenges, new implications for care
DC Schorling, A Pechmann… - Journal of …, 2020 - content.iospress.com
Abstract Spinal Muscular Atrophy (SMA) is caused by autosomal recessive mutations in
SMN1 and results in the loss of motor neurons and progressive muscle weakness. The …
SMN1 and results in the loss of motor neurons and progressive muscle weakness. The …
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an …
C Weiß, A Ziegler, LL Becker, J Johannsen… - The Lancet Child & …, 2022 - thelancet.com
Background Given the novelty of gene replacement therapy with onasemnogene
abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for …
abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for …
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
G Thomsen, AHM Burghes, C Hsieh, J Do, BTT Chu… - Nature medicine, 2021 - nature.com
Spinal muscular atrophy type 1 (SMA1) is a debilitating neurodegenerative disease resulting
from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec …
from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec …
Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening
J Glascock, J Sampson… - Journal of …, 2018 - content.iospress.com
Background: Spinal muscular atrophy (SMA) is an autosomal recessive disease
characterized by the degeneration of alpha motor neurons in the spinal cord, leading to …
characterized by the degeneration of alpha motor neurons in the spinal cord, leading to …
Nusinersen: first global approval
SM Hoy - Drugs, 2017 - Springer
Spinal muscular atrophy (SMA) is a rare autosomal recessive disorder characterized by
muscle atrophy and weakness resulting from motor neuron degeneration in the spinal cord …
muscle atrophy and weakness resulting from motor neuron degeneration in the spinal cord …
Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3–a prospective observational study
MC Walter, S Wenninger, S Thiele… - Journal of …, 2019 - content.iospress.com
Objective: Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor
neuron disease caused by loss of the SMN1 gene. Based on randomized clinical trials in …
neuron disease caused by loss of the SMN1 gene. Based on randomized clinical trials in …